Description du projet
Une nouvelle méthodologie pour le traitement des eaux usées pharmaceutiques
Les produits pharmaceutiques représentent une part importante de la contamination de l’eau. Des agents de contraste (CMA pour contrast medium agents) iodés sont employés pour l’imagerie par rayons X des tissus mous, des doses élevées étant utilisées pour chaque opération d’imagerie. Les CMA sont résistants au traitement biologique conventionnel des eaux usées et ont été détectés à des concentrations élevées, non seulement dans les effluents des stations d’épuration, mais aussi dans l’eau potable. Le projet REMEDI, financé par l’UE, formera des chercheurs en début de carrière et de futurs professionnels du domaine de l’usage efficace des ressources hydriques en environnement industriel, en se concentrant sur la pénurie d’eau provoquée par la contamination pharmaceutique. Ce projet est le fruit d’un effort conjoint entre la société Tauw GmbH, du secteur environnemental, l’université polytechnique de Milan et l’université de Warwick.
Objectif
REMEDI trains future professionals and scientists in the area of competitive use of water resources within an industry centered environment, targeting the problem of scarcity of water resources due to contamination by pharmaceuticals. Enhanced loading of water resources with pharmaceuticals is a key challenge in meeting the objectives of the EU Water Framework Directive. Iodinated X-ray contrast medium agents (CMA) are one type of the pharmaceuticals being used for the imaging of soft tissues which are typically administered in elevated doses for each imaging operation and excreted mainly nonmetabolized. The CMA are persistent during conventional biological wastewater treatments and therefore, CMA have been detected at elevated concentrations in the effluents of waste water treatment plants, surface waters, groundwater, and even in drinking water. Tauw GmbH is an environmental company which recognizes that design of strategies for treatment of water resources requires solid knowledge leading to new methods and approaches to trap pharmaceutical components in water treatment systems and in the sediments of lakes and rivers. Tauw GmbH does not have in-house resources to undertake the body of research required to set and develop. It has stimulated the REMEDI EID action, jointly with Politecnico di Milano and University of Warwick, to address these issues. Trapping of CMA involves the application of iron(Fe)- containing by-products from drinking water treatment. REMEDI aspires the ideas of a circular economy and aims at recovering the retained X-ray Contrast Media agents in water treatment systems, rivers and lakes. Novel technologies will be developed to convert CMA-loaded Fe-minerals into marketable products whose suitability will be evaluated. 5 ESR projects address these challenges with a level of interaction and synergy among academic and non-academic players leading to forming a cadre of scientists with skills apt to unravel complex environmental scenarios.
Champ scientifique
- engineering and technologyenvironmental engineeringwater treatment processesdrinking water treatment processes
- engineering and technologyenvironmental engineeringwater treatment processeswastewater treatment processes
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencesearth and related environmental scienceshydrology
- social scienceseconomics and businesseconomicssustainable economy
Mots‑clés
Programme(s)
Régime de financement
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinateur
20133 Milano
Italie